AxoGen price target raised to $50 from $45 at Canaccord

Canaccord analyst Caitlin Roberts raised the firm’s price target on AxoGen (AXGN) to $50 from $45 and keeps a Buy rating on the shares. The firm said they posted an impressive quarter even considering that Q1 was its easiest comp of the year, up 26.6% year-over-year, with double-digit growth across each target market and ramping productivity from recently hired reps.